Skip to content
Peptigraph home

GLOW

A pre-mixed blend of GHK-Cu, BPC-157 and TB-500. No controlled study has tested the blend itself; this hub covers the math and what each part has been studied for.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated Strongest evidence: Human RCT (ingredients) evidence, 4 of 4
StatusNot FDA approved · unstudied blendProhibited by WADA (S0)Full legal history

Key facts

How we verify
Class
Three-peptide blend
Pre-mixed blend
Also called
No common aliases
Vial sizes sold
50 mg, 70 mg
Community-reported sizes
Half-life
less than 30 min
IV and IM (single and repeated), rat, beagle dog · Frontiers in pharmacology 2022, PMID 36588717
FDA status
Not FDA approved · unstudied blend
Not an approved product
WADA
Prohibited (S0)
In and out of competition
Everything on GLOW

GLOW guides

DosageDoses used in published studies, with the source for each.Side effectsWhat labels and studies report, and what is unknown.Blend calculatorSplit a blend vial into per-peptide amounts and units.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.How to injectSites, syringe types and hygiene, step by step.StoragePowder and mixed vials: temperature and shelf life.For hairWhat research says about GLOW for hair.

What is in it

GHK-CuCopper tripeptideBPC-157Gastric pentadecapeptideTB-500Synthetic fragment of thymosin beta-4

Amounts per vial vary by seller. No controlled study has tested the blend itself.

Evidence at a glance

Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies. GLOW itself has not been studied; grades come from its ingredients' studies.

GLOW: studies by condition
ConditionHuman studiesAnimal studiesStudies we summarisedEvidence grade
Hair002Human observational evidence, 3 of 4GHK-Cu: Journal of cosmetic and laser therapy 2018, PMID 29482481

Grades follow our evidence scale. Summarised studies come from our evidence files for GHK-Cu, BPC-157 and TB-500, each quote checked against the abstract or label.

Compared with

GLOWvsKLOWThree-peptide blend next to four-peptide blend: evidence, dosing and legal status side by side.Not FDA approved · unstudied blendRead the comparison →

Common questions

Is GLOW FDA approved?

GLOW is Not FDA approved · unstudied blend. Products sold as research chemicals are not the approved drug and are not checked by the FDA.

What is in GLOW?

GHK-Cu, BPC-157 and TB-500, pre-mixed in one vial. Amounts per vial vary by seller and are rarely verified.

Is GLOW banned in sport?

Yes. Prohibited by WADA (S0), so it is prohibited at all times for tested athletes.

How much water goes in a 50 mg vial?

That choice only changes the concentration. With 2 mL, the vial is 25 mg/mL. The calculator converts any amount to syringe units. It does the math only and does not suggest a dose.

Sources

  1. 1US search volume and year-over-year trend, Google Keyword Planner export (Jun–Aug 2026 vs 2025)Peptigraph research · 2026peptigraph.com/methodology/Accessed 1 Oct 2026
  2. 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  3. 3United States: Not an approved product anywhere; see components (GHK-Cu, BPC-157, TB-500). Drugs@FDA (openFDA) search for the component GHK-Cu returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  4. 4Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth - safety and efficacy evaluation in a first-in-man pilot clinical study.Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology · 2018PMID 29482481Accessed 2 Oct 2026
  5. 5Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion.Cardiovascular research · 2025PMID 41229390Accessed 2 Oct 2026
  6. 6Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.Frontiers in pharmacology · 2022PMID 36588717Accessed 2 Oct 2026

Found an error? Report a correction.